ATM-5292 / Atomic AI - LARVOL DELTA

Discovery and preclinical evaluation of ATM-5292: A potent and selective RNA targeting splice modulator for the treatment of non small cell lung cancer (NSCLC) and breast cancer, enabled by the PARSE™ machine learning platform (AACR 2025) - "In summary, ATM-5292 is a promising, first-in-class dual mRNA degrader with potent anti-tumor activity in preclinical models. It is well-positioned for further GLP toxicology studies and potential clinical development."

Late-breaking abstract • Machine learning • Preclinical • Breast Cancer • Colorectal Cancer • Hematological Malignancies • Leukemia • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOXM1